Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02285634 · ClinicalTrials.gov registry record · NA

The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.

A NA study, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
68
Enrollment target

NCT02285634: Completed NA study, sponsored by Mayo Clinic.

NCT02285634 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 68 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02285634, a NA study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
68 participants
Enrollment target

Study Summary

Nosebleeds (epistaxis) are a frequent cause of emergency department visits, reportedly inciting 1 in 200 visits. They are most common in those less than ten and older than seventy, often occurring in the winter months secondary to dry indoor heating. Epistaxis is associated with elevated blood pressures, but it is controversial whether hypertension is actual a contributing cause. In non-life-threatening epistaxis, the first step in management is commonly the application of a topical vasoconstrictive medication. In many cases this will lead to cessation of the bleeding or facilitate the exam in those that continue to bleed. Frequently used medications include phenylephrine, oxymetazoline, and lidocaine with epinephrine. Classic teaching has been to avoid the use of these medications in patients with elevated blood pressures due to concerns of inducing hypertensive crisis. Strict avoidance of topical vasoconstrictors in this patient group with epistaxis severely limits the treatment options for a many patients given the association between the two conditions. Though universally taught, the actual effect of these agents on blood pressure remains unquantified. Studies investigating the prevention of nose bleeding during nasotracheal intubations suggest that the effect might be minor with little variation between agents. Clinical question: What is the effect of commonly used intranasal vasoconstrictors on blood pressure in volunteers without a history of hypertension.

Interventions

  • DRUG Oxymetazoline 0.05%
  • DRUG Phenylephrine 0.25%
  • DRUG Lidocaine 1% plus epinephrine 1:100,000
  • DRUG Bacteriostatic 0.9% NaCL

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2014-11
Est. Completion 2017-12-22
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT02285634

The ClinicalTrials.gov registry entry for NCT02285634 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Oxymetazoline 0.05% is the first listed.

NCT02285634 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02285634 about?

NCT02285634 is a clinical study titled "The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.". Nosebleeds (epistaxis) are a frequent cause of emergency department visits, reportedly inciting 1 in 200 visits. They are most common in those less than ten and older than seventy, often occurring in the winter months secondary to dry indoor heating. Epistaxis is associated with elevated blood press...

What is the current status of trial NCT02285634?

This trial is currently completed. It is a NA study. The enrollment target is 68 participants. The study started on 2014-11. Estimated completion is 2017-12-22.

What interventions are being tested in trial NCT02285634?

The interventions under investigation include: Oxymetazoline 0.05% (DRUG), Phenylephrine 0.25% (DRUG), Lidocaine 1% plus epinephrine 1:100,000 (DRUG), Bacteriostatic 0.9% NaCL (DRUG).

Who is sponsoring clinical trial NCT02285634?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.